Indaptus Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Indaptus Therapeutics, Inc.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
- Other Names / Subsidiaries
- Decoy Biosystems
- Intec Parent, Inc.
- Intec Pharma Ltd.